Photo has been modified. Courtesy of Sanofi.
Framingham, Massachusetts will be home to global pharmaceutical giant Sanofi’s newly opened digitally enabled, continuous manufacturing facility to usher in the next generation of biotech manufacturing.
The facility features leading-edge technology that connects the production process with research and development to improve the commercialization of novel medicines for patients.
“Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility,” said Philippe Luscan, executive vice president of global industrial affairs at Sanofi. “This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry.”
Sanofi has been building the facility, which cost nearly $5.2 billion, for the last five years.
The facility features new connected and intelligent equipment, process technology and solutions to augment operators.
“It will allow us to deploy advanced data analytics solutions to further improve the quality, yields and reliability of our facilities and optimize our inventories and logistic flow,” Sanofi said.
Production and data will be documented in real time, resulting in a paperless manufacturing solution with electronic batch records, review and right time release and real-time process control.
Sensors will share information about the drugs and create more than 3 billion data points from 5,000 parameters for one standard batch. When the data are analyzed, employees can access the findings to better understand the complexities of the process.
Sanofi’s digital transformation of its manufacturing network is a major aspect of its goal to leverage better use of data to optimize manufacturing processes. Digitization could help the company increase efficiencies and improv the agility needed to respond to ever-changing patient needs. What’s more, going digital will speed up the commercialization of new medicines from Sanofi’s research and development pipeline.
“With increasing advances in medical science and innovation, complex medicines are set to become even more important in improving people’s health worldwide,” Sanofi said in an interactive multichannel news release. “To keep pace with this shift, Sanofi is committed to ensuring our industrial capabilities are as innovative as the drugs in our pipeline.”
Send this to a friend